Mixed early data on Agios' AG-270 suggest combo therapy could be way forward
As Agios suspected, the profile of its experimental drug AG-270 is likely tailored best as part of a combination therapy.
On Sunday, the drugmaker $AGIO unveiled initial early-stage data on the drug in patients with MTAP-deleted tumors. MTAP is a ubiquitous housekeeping gene key to biochemical salvage processes — and is found in a region that is often expunged in a wide variety of cancers.
AG-270 is designed to inhibit methionine adenosyltransferase II alpha (MAT2A) — a metabolic enzyme in charge of producing S-Adenosyl-L-methionine (SAM), which is a compound that regulates gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in MTAP, and the drug is therefore engineered to inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.